Citigroup
SIOX

Citigroup’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Citigroup’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,404
Closed -$7K – 7837
2019
Q4 		$7K Hold
1,404
– – ﹤0.01% 7326
2019
Q3 		$9K Hold
1,404
– – ﹤0.01% 7149
2019
Q2 		$9K Sell
1,404
-246
-15% -$1.87K ﹤0.01% 7351
2019
Q1 		$18K Sell
1,650
-1,038
-39% -$10.3K ﹤0.01% 7020
2018
Q4 		$21K Buy
2,688
+838
+45% +$12.1K ﹤0.01% 6864
2018
Q3 		$36K Sell
1,850
-1,738
-48% -$31.6K ﹤0.01% 6785
2018
Q2 		$65K Buy
3,588
+2,688
+299% +$39.6K ﹤0.01% 6087
2018
Q1 		$10K Buy
900
+412
+84% +$6.62K ﹤0.01% 7067
2017
Q4 		$21K Sell
488
-1,787
-79% -$80.2K ﹤0.01% 6721
2017
Q3 		$125K Sell
2,275
-850
-27% -$143K ﹤0.01% 5384
2017
Q2 		$580K Buy
+3,125
New +$548K ﹤0.01% 3853

Other funds holding SIOX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citigroup's SIOX Position: Q1 2020 in Review

Citigroup sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2020, closing a stake of 5 shares — an estimated $18 sold.

Citigroup first reported a position in SIOX in Q4 2015 and held it in 17 quarters. The position peaked at $5.16M in Q2 2017. 42 funds tracked by Wall St. Rank hold SIOX as of Q1 2020.

  • Citigroup reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Citigroup sold 5 Sio Gene Therapies Inc. Common Stock shares in Q1 2020, an estimated $18.
  • Citigroup first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2015 and held it in 17 quarters.
  • Citigroup's Sio Gene Therapies Inc. Common Stock position peaked at $5.16M in Q2 2017.
  • 42 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2020.

Based on Citigroup's 13F filing for Q1 2020, filed 12 May 2020.